WordPress database error: [Error writing file '/tmp/MYaJqJ1N' (Errcode: 28 - No space left on device)]
SELECT t.*, tt.*, tr.object_id FROM wp_terms AS t INNER JOIN wp_term_taxonomy AS tt ON t.term_id = tt.term_id INNER JOIN wp_term_relationships AS tr ON tr.term_taxonomy_id = tt.term_taxonomy_id WHERE tt.taxonomy IN ('category', 'post_tag', 'post_format') AND tr.object_id IN (147741, 162604, 163902, 167009, 212475, 231798, 242844, 256447, 294011, 298213, 366361, 368989, 386479, 405285, 422924, 431098, 432622, 445525, 446322, 447707) ORDER BY t.name ASC

Complement Archives - Newsemia

Tag : Complement

Uncategorized

Discovery of 4-((2S,4S)-4-Ethoxy-1-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)piperidin-2-yl)benzoic Acid (LNP023), a Factor B Inhibitor Specifically Designed To Be Applicable to Treating a Diverse Array of Complement Mediated Diseases.

Newsemia
Related Articles Discovery of 4-((2S,4S)-4-Ethoxy-1-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)piperidin-2-yl)benzoic Acid (LNP023), a Factor B Inhibitor Specifically Designed To Be Applicable to Treating a Diverse Array of Complement Mediated Diseases....
Uncategorized

IVERIC bio’s Zimura®, a Novel Complement C5 Inhibitor, Met its Primary Endpoint and Reached Statistical Significance in a Phase 2b Randomized, Controlled Clinical Trial in Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

Newsemia
NEW YORK–(BUSINESS WIRE)–IVERIC bio, Inc. announced initial topline data confirming that Zimura® met its prespecified primary endpoint in its Phase 2b clinical trial. Source link...

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy